Fraunhofer-gesellschaft Zur Foerderung Der Angewandten Forschung E.v.

Markus Sack

Rainer Fischer

Holger Spiegel

Andreas Reimann

Alexander Boes

Gueven Edgue

Veronique Beiss

Stefan Schillberg

Simon Vogel

Matthias Buntru

Yu-Cai Liao

Neil Emans

Daniel Blessing

J&ouml;rg N&auml;hring

Sabine Zimmerman

Tanja Holland

Michael Monecke

Edgü GÜVEN

Carmen Vaquero-Martin

The present disclosure pertains to novel cell cultivation and cell and/or cell-derived product production processes that have advantages over currently existing fermentation strategies. The processes and methods according to the present disclosure may be used for an efficient supply of highly viable and metabolically active eukaryotic cells for transient production platforms, as an alternative production process with advantages over currently applied processes (batch, fed-batch or perfusion strategies) and for generating metabolically highly active biomass for subsequent use for transient expression systems or infection by a virus or pseudovirus or in cell-free systems.

Fermentation systems

The technology provided herein relates to novel malaria vaccines composed of different recombinant proteins, in particular recombinant fusion proteins comprising several differentantigens from the pre-erythrocytic, the blood, and the sexual parasite main stages. The proteins may be used in a mixture vaccine formulation to elicit protective immune responses in humans. Nucleic acid molecules encoding said recombinant proteins, vectors and host cells containing the nucleic acids and methods for preparation and producing such proteins are also disclosed, as well as antibodies induced or generated by the use of said malaria vaccines and the use of such antibodies or recombinant derivatives for passive immunotherapy.

Three-component-multistage malaria vaccine

The present disclosure relates to novel malaria vaccines composed of different recombinant proteins, in particular recombinant fusion proteins comprising several differentantigens from the pre-erythrocytic the blood, and the sexual parasite stages. The proteins and/or fusion proteins will be used in a mixture vaccine formulation to elicit protective immune responses in humans. Nucleic acid molecules encoding said recombinant proteins, vectors, host cells containing the nucleic acids and methods for preparation and producing such proteins; Antibodies induced or generated by the use of said malaria vaccines or said nucleic acid molecules encoding said proteins and/or fusion proteins and the use of such antibodies or recombinant derivatives for passive immunotherapy.

Multi-component-multistage malaria vaccines

The technology provided herein generally relates to novel fusion proteins suitable as human and/or animal vaccines against parasites or pathogens of the phylum Apicomplexa. In particular, the present disclosure relates to novel fusion proteins as a basis for vaccines againstparasites, includingand. Nucleic acid molecules encoding said fusion proteins, vectors, host cells containing the nucleic acids and methods for preparation and producing such fusion proteins; antibodies induced or generated by the use of said fusion proteins or said nucleic acid molecules encoding said fusion proteins and the use of such antibodies or recombinant derivatives for passive immunotherapy; methods for producing such fusion proteins; compositions and methods for using such fusion proteins for the prevention and treatment of malaria are also encompassed by the present disclosure.

Vaccines against apicomplexan pathogens

The present invention is drawn to a fusion protein containing at least one binding domain that specifically recognizes an eptitope of a plant pathogen and at least one additional domain made from a protein or peptide sequence which is toxic to the pathogen or detrimental the replication, transmission or life cycle of the pathogen. The present invention is further drawn to a pathogenocide made from the binding domain, a cellular targeting sequence and/or membrane localization sequence that leads to membrane anchoring. The present invention is further drawn to nucleotide sequences encoding fusion proteins and pathogenocides and to vectors containing the nucleotide sequences; as well as methods of making the fusion proteins and pathogencides and methods of making pathogen resistant plants, plant cells, or plant tissues with the fusion proteins and pathogenocides.

Molecular pathogenicide mediated plant disease resistance

Growing community of inventors

Alsdorf, Germany

Markus Sack